Verona Pharma (VRP)

 

VRP Share PerformanceMore

52 week high200.00 26/03/18
52 week low100.00 15/02/18
52 week change 22.00 (16.54%)
4 week volume1,660,735 30/03/18
price155.00
price date1524668079
close155.00

Media for (VRP)

Presenter: Jan-Anders Karlsson
28/07/2014

Latest NewsMore

Verona Pharma chief medical officer Kenneth Newman to leave

Respiratory diseases treatment developer Verona Pharma said chief medical officer Kenneth Newman had resigned, effec...

Broker Forecast - Shore Capital issues a broker note on Verona Pharma PLC

Shore Capital today initiates coverage of Verona Pharma PLC (LON:VRP) with a buy investment rating and price target o...

Verona Pharma Announces Departure of Chief Medical Officer

Verona Pharma Announces Departure of Chief Medical Officer LONDON, April 11, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma" or "the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, today announces that Kenn...

Verona Pharma Reports Positive Top-Line Data from Phase 2b Clinical Trial of RPL554 for Maintenance Treatment of COPD

Verona Pharma Reports Positive Top-Line Data from Phase 2b Clinical Trial of RPL554 for Maintenance Treatment of COPD Primary endpoint met; RPL554 produced clinically and statistically significant improvements in lung function at all dose levels Clinically relevant secondary endpoints were also met, including statistically significant, progressive improvemen...

Broker Forecast - N+1 Singer issues a broker note on Verona Pharma PLC

N+1 Singer today reaffirms its strong buy investment rating on Verona Pharma PLC (LON:VRP) and raised its price targ...

Verona Pharma to Present at Upcoming Healthcare Investor Conferences

Verona Pharma to Present at Upcoming Healthcare Investor Conferences LONDON, March 15, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, today announced that Company ma...

Verona Pharma plc: 2017 Annual Report and Accounts and Notice of AGM

Verona Pharma plc: 2017 Annual Report and Accounts and Notice of AGM March 9, 2018, LONDON - Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, is pleased to confirm that a hard copy of the Annual Repor...

Verona Pharma plc : Grant of Options and RSUs and PDMR Dealings

Verona Pharma plc: Grant of Options and RSUs and PDMR Dealings March 9, 2018, LONDON - Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it granted the following options over ordinary sha...

Fundamental DataMore

EPS-0.74
Dividend yield0 %

Latest discussion posts More

  • Re: CEO Interview

    Mol. We must expect CEO to be upbeat but if the product performance is so far above all current competitors then surely upon FDA certification with only 105 mill shares in ...
    23-Apr-2018
    millwallfan
  • CEO Interview

    short interview published 200418 http://www.youtube.com/watch?v=Sid3BGs7EEU mol
    23-Apr-2018
    mol42
  • Re: CMO leaving

    I would have hoped the ceo would issue a statement as human nature will assume the worst case scenario and the market reacted accordingly
    13-Apr-2018
    millwallfan

Users' HoldingsMore

Users who hold Verona Pharma also hold..

Codes & Symbols

ISINGB00BYW2KH80
SymbolsVRP, LSE:VRP, VRP.L, VRP:LN, LON:VRP, XLON:VRP